solid driven upsid product line partial due season off-set
on-going neulasta weak lower end revs/ep guidanc rais importantli
pipelin progress show respons gi tumor advanc
pivot ph nsclc studi biosimilar late stage franchis advanc nice overal
good result despit headwind legaci busi
legaci franchis sensipar gener neulasta face biosimilar competit
unlik diminish despit onpro retain solid share face tremend
head wind despit overal busi line upper end guidanc
oper margin ahead consensu revenu line gener line
ahead total product sale vs typic season prolia
enbrel factor annual guidanc model overal increas
ep new pt base price-to-earnings analysi
opex margin vs vs consensu tax rate slightli
higher vs boost lower share count vs
repurchas stock line estim project
stock buyback
rais lower end revenu guidanc cowen
rais lower end non-gaap ep
cowen
importantli kra inhibitor immin move pivot studi
monotherapi lung cancer drug also show respons
appendic cancer qd dose monotherapi arm studi fulli
enrol enrol on-going combo arm wclc
provid data updat lung cancer like also updat data includ gi tumor
esmo
updat encourag recent analysi medicin chemistri structur
drug suggest set high bar competit follow
pass medchem review-solubl volume dist improv call
mention see solubl limit base pk/pd
profil on-going studi updat encourag
fact drug also show initi respons gi tumor hand
initi patient address one linger concern data
respons gi time patient lower dose
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
district court decis enbrel patent
infring suit sandoz
updat data phase studi kra
updat sensipar gener litig
potenti data bite platform
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma earli stage oncolog pipelin solid liquid tumor
biosimilar franchis aimovig also provid attract growth venu
launch kanjinti biosimilar herceptin mvasi biosimilar avastin us
dec pdufa date abp biosimilar remicad may get approv
data abp biosimilar rituxan expect nhl sizabl
lucr market sustain growth franchis sale
cowen compani
cowen compani
growth us ex-u growth y/i erythropoietin enbrel growth us ex-u sale g-csf growth quarter-over-quart us ex-u us ex-u dmab growth us ex-u kyproli growth us ex-u us ex-u us ex-u probabl product sale growth revenu growth good sold margin margin product incom growth gaap growth share outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
